Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Blood Safety
Pathogen safety reconfirmed for Prolastin
October 5th, 2006
Talecris Biotherapeutics presented data reconfirming the pathogen safety profile for Prolastin (Alpha-1-Proteinase Inhibitor (Human)). Information shared at the 2006 Annual Congress of the European Respiratory Society demonstrated that the manufacturing process for Prolastin significantly removes or inactivates key viruses as well as pathogenic prions such as those associated with variant Creutzfeldt-Jakob Disease. Furthermore, the high margin of pathogen safety is affirmed by nearly two decades of clinical experience and more than 1.5 million infusions of Prolastin for alpha-1 antitrypsin augmentation therapy without a documented report of a virus...
Source: Blood Weekly (2006-10-05)
|
